Methods of treating mixed dyslipidemia

Abstract

The present disclosure relates to, inter alia, methods of treating mixed dyslipidemia with ethyl eicosapentaenoate.

I/We claim: 
     
         1 . A method of treating high triglycerides comprising administering eicosapentaenoic acid (EPA) and a statin to a subject having a baseline LDL-C level of at least 100 mg/dl, a baseline non-HDL-C level of at least 130 mg/dl, and a baseline triglyceride level of at least 250 mg/dl, wherein the EPA is in a capsule in an amount of at least about 95%, by weight, of all fatty acids present in the capsule, the statin and the EPA are co-administered in a same dosage unit, and the EPA is administered to the subject in an amount sufficient to provide a dose of 2500 mg to about 10,000 mg of the EPA per day. 
     
     
         2 . The method of  claim 1  comprising administering the statin and the EPA for a period of time to reduce an Apo-B level and the baseline non-HDL-C level in the subject. 
     
     
         3 . The method of  claim 1  comprising administering the statin and the EPA for a period of time to reduce an Apo-B level in the subject without increasing the baseline LDL-C level in the subject. 
     
     
         4 . The method of  claim 1  comprising administering the statin and the EPA for a period of time to reduce an Apo-B level in the subject compared to a control subject who has a baseline triglyceride level of at least about 250 mg/dl and has received the statin but not the EPA. 
     
     
         5 . The method of  claim 1 , wherein the EPA is ethyl-EPA. 
     
     
         6 . The method of  claim 1 , wherein the subject has a baseline triglyceride level of at least 500 mg/dl. 
     
     
         7 . The method of  claim 1 , wherein the subject has a baseline triglyceride level of about 500 mg/dl to about 1500 mg/dl. 
     
     
         8 . The method of  claim 1 , wherein the subject is administered the statin and the EPA for a period of time of at least about 2 years. 
     
     
         9 . The method of  claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 15%. 
     
     
         10 . The method of  claim 1 , wherein the subject exhibits a reduction in triglyceride levels of at least about 20%. 
     
     
         11 . The method of  claim 1 , wherein the statin is selected from lovastatin, mevastatin, pitavastatin, pravastatin, rosuvastatin, fluvastatin, atorvastatin and simvastatin.